These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 18418698)

  • 1. Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience.
    Auberger J; Clausen J; Willenbacher W; Erdel M; Gunsilius E; Petzer A; Gastl G; Nachbaur D
    Int J Hematol; 2008 May; 87(4):382-386. PubMed ID: 18418698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
    Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
    Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.
    Krejci M; Doubek M; Dusek J; Brychtova Y; Racil Z; Navratil M; Tomiska M; Horky O; Pospisilova S; Mayer J
    Ann Hematol; 2013 Oct; 92(10):1397-403. PubMed ID: 23728608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.
    Stelljes M; Middeke JM; Bug G; Wagner-Drouet EM; Müller LP; Schmid C; Krause SW; Bethge W; Jost E; Platzbecker U; Klein SA; Schubert J; Niederland J; Kaufmann M; Schäfer-Eckart K; Schaich M; Baldauf H; Stölzel F; Petzold C; Röllig C; Alakel N; Steffen B; Hauptrock B; Schliemann C; Sockel K; Lang F; Kriege O; Schaffrath J; Reicherts C; Berdel WE; Serve H; Ehninger G; Schmidt AH; Bornhäuser M; Mikesch JH; Schetelig J;
    Lancet Haematol; 2024 May; 11(5):e324-e335. PubMed ID: 38583455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
    Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
    Versluis J; Hazenberg CL; Passweg JR; van Putten WL; Maertens J; Biemond BJ; Theobald M; Graux C; Kuball J; Schouten HC; Pabst T; Löwenberg B; Ossenkoppele G; Vellenga E; Cornelissen JJ;
    Lancet Haematol; 2015 Oct; 2(10):e427-36. PubMed ID: 26686044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
    Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outcome of relapsed childhood acute lymphoblastic leukemia after allogeneic hematopoietic stem-cell transplantations: A single-center experience.
    Aygüneş U; Karagün BŞ; Şaşmaz I; Antmen AB
    Clin Transplant; 2024 May; 38(5):e15366. PubMed ID: 38775798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study.
    Tang W; Fan X; Wang L; Hu J
    Medicine (Baltimore); 2015 Apr; 94(15):e706. PubMed ID: 25881847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
    Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinic Outcome of FLAG Regimen treating Patients with Refractory and Relapse Acute Myeloid Leukemia].
    Wang LJ; Ding J; Zhu CY; Yang H; Wang HX; Jing Y; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):19-24. PubMed ID: 26913387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
    Guolo F; Minetto P; Clavio M; Miglino M; Di Grazia C; Ballerini F; Pastori G; Guardo D; Colombo N; Kunkl A; Fugazza G; Rebesco B; Sessarego M; Lemoli RM; Bacigalupo A; Gobbi M
    Am J Hematol; 2016 Aug; 91(8):755-62. PubMed ID: 27084986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.
    Gill H; Yim R; Pang HH; Lee P; Chan TSY; Hwang YY; Leung GMK; Ip HW; Leung RYY; Yip SF; Kho B; Lee HKK; Mak V; Chan CC; Lau JSM; Lau CK; Lin SY; Wong RSM; Li W; Ma ESK; Li J; Panagiotou G; Sim JPY; Lie AKW; Kwong YL
    Cancer Med; 2020 May; 9(10):3371-3382. PubMed ID: 32187883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
    Fong CY; Grigoriadis G; Hocking J; Coutsouvelis J; Muirhead J; Campbell P; Paul E; Walker P; Avery S; Patil S; Spencer A; Schwarer A; Wei A
    Leuk Lymphoma; 2013 Feb; 54(2):336-41. PubMed ID: 22812445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary treatment of leukemia relapses after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning second transplantation from the original donor.
    Leung AY; Tse E; Hwang YY; Chan TS; Gill H; Chim CS; Lie AK; Kwong YL
    Am J Hematol; 2013 Jun; 88(6):485-91. PubMed ID: 23512868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
    Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
    Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Malard F; Labopin M; Stuhler G; Bittenbring J; Ganser A; Tischer J; Michallet M; Kröger N; Schmid C; Huynh A; Hallek M; Savani BN; Mohty M; Nagler A
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):278-284. PubMed ID: 27816650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
    Aldoss I; Ji L; Haider M; Pullarkat V
    Acta Haematol; 2014; 131(4):202-7. PubMed ID: 24296475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.